 | Up a level |
Gold, Ralf; Piani-Meier, Daniela; Kappos, Ludwig; Bar-Or, Amit; Vermersch, Patrick; Giovannoni, Gavin; Fox, Robert J; Arnold, Douglas L; Benedict, Ralph H B; Penner, Iris-Katharina; Rouyrre, Nicolas; Kilaru, Ajay; Karlsson, Göril; Ritter, Shannon; Dahlke, Frank; Hach, Thomas; Cree, Bruce A C (2022). Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of neurology, 269(9), pp. 5093-5104. Springer 10.1007/s00415-022-11166-z
Chan, Andrew; Cutter, Gary; Fox, Robert J; Xiao, James; Lewin, James B; Edwards, Michael R (2017). Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. Journal of comparative effectiveness research, 6(4), pp. 313-323. Future Medicine 10.2217/cer-2016-0085
Fox, Robert J; Chan, Andrew; Zhang, Annie; Xiao, James; Levison, Dane; Lewin, James B; Edwards, Michael R; Marantz, Jing L (2016). Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Current medical research and opinion, 33(2), pp. 1-23. Informa Healthcare 10.1080/03007995.2016.1248380
Fox, Robert J; Chan, Andrew; Gold, Ralf; Phillips, J Theodore; Selmaj, Krzysztof; Chang, Ih; Novas, Mark; Rana, Jitesh; Marantz, Jing L (2016). Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations. Neurology. Clinical practice, 6(3), pp. 220-229. American Academy of Neurology 10.1212/CPJ.0000000000000238
